Baltimore -aHUS First Since COVID
Zoom has helped with keeping aHUS advocacy going during the restrictions resulting from the COVID pandemic. Starting a zoom meeting always…
Is incidence of aHUS really “2 per million”?
I know it should not matter so much but whenever I see incidence and prevalence figures for aHUS in articles etc,…
aHUS Community Advisory Board News
Two updates on the Global aHUS Community Advisory Board. There is some information about the inaugural set of CAB / PHARMA…
aHUS trial watch 17- NM8074
Another trial of a complement inhibitor for aHUS treatment has been announced , it is for something currently called NM8074. Full…
A call for interest in joining the aHUS CAB
This time last year a couple of dozen people with an interest in global aHUS advocacy were discussing and deciding on…
aHUS is confusing
Sometimes it can be confusing being an aHUS patient. Even to knowing whether you are really an aHUS patient. Even if…
The aHUS Global Advocate: Our Vol 6 Newsletter
We’re pleased to announce that our latest edition of The aHUS Global Advocate newsletter has been released (Vol 6, Jan 2023)…
What’s New in aHUS Research? Jan 2023 Edition
Sometimes there are fascinating articles related to atypical HUS which people might miss, and it’s then that it’s particularly helpful to…
aHUS Global Action – Meet Trustee K Grey
As advocates for the rare disease atypical haemolytic uraemic syndrome (atypical HUS), there’s only one group of patients and caregivers whose…
- Go to the previous page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- …
- 81
- Go to the next page